Currently, the company sits on a 27-acre lot, and manufacturesdrugs at its 127,000-sf plant in a quantity only large enough fortesting purposes. With the new facility, Human Genome Sciences willproduce novel human hormones and proteins, as well as humanantibody drugs. "We appreciate the strong support of the financialcommunity which has enabled Human Genome Sciences to finance thisimportant expansion," says company Senior Vice President Steven C.Mayer.

Gilbane Building Company is leading the construction effort andexpects to complete the 360,000-sf development half way through2003. Just four months ago, Human Genome Sciences beganconstruction on another structure, which will be nearly 420,000-sfin size.

Continue Reading for Free

Register and gain access to:

  • Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.